Warfarin and aspirin as thromboprophylaxis in atrial fibrillation

British Journal of Clinical Pharmacology

Volumn 41, Issue 5, 1996, Pages 369-379

  Lip, G Y H ^a   Lowe, G D O ^b  

^a UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

^b GLASGOW ROYAL INFIRMARY   (United Kingdom)

Author keywords

aspirin; atrial fibrillation; stroke; thromboembolism; warfarin

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; WARFARIN;

ADULT; AGED; CLINICAL TRIAL; DRUG EFFICACY; DRUG INDICATION; ECHOCARDIOGRAPHY; FEMALE; HEART ATRIUM FIBRILLATION; HIGH RISK POPULATION; HUMAN; MALE; MORTALITY; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; STROKE; THROMBOEMBOLISM;

EID: 0029995125     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1996.03384.x     Document Type: Review

References (83)

1. Kannell WB, Abbott RD, Savage DD, McNamara PM. Epidemiological features of chronic atrial fibrillation. The Framingham Study. N Engl J Med 1982; 306: 1018-1022.
2. Wolf PA, Abbot RD, Kannell WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham study. Stroke 1991; 22: 983-988.
3. Lake FR, Cullen KJ, de Klerk NH, McCall MG, Rosman DL. Atrial fibrillation and mortality in an elderly population. Aust N Z J Med 1989; 19: 321-326.
4. Hill JD, Mottram EM, Killeen PD. Study of the prevalance of atrial fibrillation in general practice patients over 65 years of age. J R Coll Gen Pract 1987; 37: 172-173.
5. Rose G, Baxter PJ, Reid DD, McCartney P. Prevalance and prognosis of electrocardiographic findings in middle-aged men. Br Heart J 1978; 40: 636-643.
6. Camm JC, Evans KE, Ward DE, Martin A. The rhythm of the heart in active elderly subjects. Am Heart J 1980; 99: 598-603.
7. Kennedy RD, Caird FI. The application of the Minnesota code to population studies of the electrocardiogram in the elderly. Gerontology Clinics 1972; 14: 5-16.
8. Campbell A, Caird FI, Jackson TFM. Prevalance of abnormalities of electrocardiogram in old people. Br Heart J 1974; 36: 1005-1011.
9. Sudlow CM, Rodgers H, Kenny RA, Thomson RG. Service provision and use of anticoagulants in atrial fibrillation. Br Med J 1995; 311: 558-561.
10. Lip GYH, Beevers DG, Coope JR. ABC of Atrial Fibrillation. Atrial fibrillation in hospital and general practice. Br Med J 1996; 312: 175-178.
11. Lowe GDO, Jaap AJ, Forbes CD. Relation of atrial fibrillation and high haematocrit to mortality in acute stroke. Lancet 1983; i: 784-786.
12. Sandercock P, Bamford J, Dennis M, et al. Atrial fibrillation and stroke: prevalence in different types of stroke and influence on early and long term prognosis (Oxfordshire community stroke project) Br Med J 1992; 305: 1460-1465.
13. Chesebro JH, Fuster V, Halperin JL Atrial fibrillation - risk marker for stroke. N Engl J Med 1990; 323: 1556-1558.
14. Wolf PA, Dawber TR, Thomas HE Jr, Kannel WB. Epidemiologie assessment of chronic atrial fibrillation and risk of stroke: the Framingham study. Neurology 1978; 28: 973-977.
15. Shimomura K, Ohe T, Uehara S, Matsuhisa M, Kamakura S, Sato I. Significance of atrial fibrillation as a precursor of embolism. Am J Cardiol 1989; 63: 1405-1407.
16. Wolf PA, Abott RD, Kannell WB. Atrial fibrillation: a major contributor to stroke in the elderly. The Framingham Study. Arch Intern Med 1987; 147: 1561-1564.
17. Petersen P, Boysen G, Godtfredsen J, Andersen ED, Andersen B. Placebo controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: the Copenhagen AFASAK study. Lancet 1989; i: 175-179.
18. Stroke Prevention in Atrial Fibrillation Investigators. Stroke Prevention in Atrial Fibrillation Study. Final results. Circulation 1991; 84: 527-539.
19. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Arch Intern Med 1994; 154: 1449-1457.
20. Yamanouchi H, Tomonaga M, Shimada H, Matsushita S, Kuramoto K, Toyokura Y. Nonvalvular atrial fibrillation as a cause of fatal massive cerebral infarction in the elderly. Stroke 1989; 20: 1653-1656.
21. Petersen P, Madsen EB, Brun B, Pedersen F, Gyldensted C, Boysen G. Silent cerebral infarction in chronic atrial fibrillation. Stroke 1987; 18: 1098-1100.
22. Cabin HS, Clubb S, Hall C, Perlmutter RA, Feinstein AR. Risk for systemic embolization of atrial fibrillation without mitral stenosis. Am J Cardiol 1990; 65: 1112-1116.
23. Cairns JA, Connolly SJ . Nonrheumatic atrial fibrillation. Risk of stroke and role of antithrombotic therapy. Circulation 1991; 84: 469-481.
24. Stroke Prevention in Atrial Fibrillation Investigators. Predictors of thromboembolism in atrial fibrillation: I. Clinical features of patients at risk. Ann Intern Med 1992; 116: 1-5.
25. Stroke Prevention in Atrial Fibrillation Investigators. Predictors of thromboembolism in atrial fibrillation: II. Echocardiographic features of patients at risk. Ann Intern Med 1992; 116: 6-12.
26. Griffith GC, Stragnell R, Levinson DC, Moore FJ, Ware AG. Study of beneficial effects of anticoagulant therapy in congestive heart failure. Ann Intern Med 1952; 37: 867-887
27. Takahashi N, Imataka K, Seki A, Fujii J. Left atrial enlargement in patients with paroxysmal atrial fibrillation. Jpn Heart J 1982; 23: 677-683.
28. Sanfilippo AJ, Abascal VM, Sheehan M, Oertel LB, Harrigan P, Hughes RA, Weyman AE. Atrial enlargement as a consequence of atrial fibrillation. A prospective echocardiographic study. Circulation 1990; 82: 792-797.
29. Sosa-Suarez G, Lampert S, Graboys TB, Ravid S, Lown B. Changes in left atrial size due to chronic atrial fibrillation. J Am Coll Cardiol 1989; 13: 206A.
30. Petersen P, Kastrup J, Brinch K, Godtfredsen J, Boysen G. Relation between left atrial dimension and duration of atrial fibrillation. Am J Cardiol 1987; 60: 382-384.
31. Caplan LR, D'Cruz I, Hier DB, Reddy H, Shah S. Atrial size, atrial fibrillation and stroke. Ann Neurol 1986; 19: 158-161.
32. Daniel WG, Nellessen U, Schroder E, Nonnast-Daniel B, Bednarski P, Nikutla P, Lichtlen PR. Left atrial spontaneous echo contrast in mitral valve disease: an indicator for an increased thromboembolic risk. J Am Coll Cardiol 1988; 11: 1204-1211.
33. Davidson E, Rotenberg Z, Weinberger I, Fuchs J, Agmon J. Diagnosis and characteristics of lone atrial fibrillation. Chest 1989; 95: 1048-1050.
34. Sigel B, Coelho JCU, Spigos DG, et al. Ultrasonography of blood during stasis and coagulation. Invest Radiol 1981; 16: 71-76.
35. Black IW, Hopkins AP, Lee LC, Walsh WF, Jacobson BM. Left atrial Spontaneous Echo Contrast: A Clinical and Echocardiographic Analysis. J Am Coll Cardiol 1991; 18: 398-404.
36. Manning WJ, Silverman DI, Gordon SPF, Krumholz HM, Douglas PS. Cardioversion from atrial fibrillation without prolonged anticoagulation with use of transesophageal echocardiography to exclude the presence of atrial thrombi. N Engl J Med 1993; 328: 750-755.
37. Wolf PA, Kannel WB, McGee DL, Meeks SL, Bharucha NE, McNamara PM. Duration of atrial fibrillation and imminence of stroke: the Framingham study. Stroke 1983; 14: 664-667.
38. Petersen P. Thromboembolic complications in atrial fibrillation. Stroke 1990; 21: 4-13.
39. Petersen P. Thromboembolic complications of atrial fibrillation and their prevention: A review. Am J Cardiol 1990; 65: 24C-28C.
40. Roy D, Marchand E, Gagne P, Chabot M, Cartier R. Usefulness of anticoagulant therapy in the prevention of embolic complications of atrial fibrillation. Am Heart J 1986; 112: 1039-1043.
41. Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low-dose warfarin on the risk of stroke in patients with non-rheumatic atrial fibrillation. N Engl J Med 1990; 323: 1505-1511.
42. Connolly SJ, Laupacis A, Gent M, Roberts RS, Cairns JA, Joyner C. Canadian Atrial Fibrillation Anticoagulation (CAFA)Study. J Am Coll Cardiol 1991; 18: 349-355.
43. Ezekowitz MD, Bridgers SL, James KE et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. N Engl J Med 1992; 327: 1406-1412.
44. Stroke Prevention in Atrial Fibrillation Investigators. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II study. Lancet 1994; 343: 687-691.
45. EAFT (European Atrial Fibrillation Trial) Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 1993; 342: 1255-1262.
46. Albers GW. Atrial fibrillation and stroke. Three new studies, three remaining questions. Arch Intern Med 1994; 154: 1443-1448.
47. Gottlieb LK, Salem-Schatz S. Anticoagulation in atrial fibrillation. Does efficacy in clinical trials translate into effectiveness in practice? Arch Intern Med 1994; 154: 1945-1953.
48. Sweeney KG, Pereira Gray DJ, Steele RJF, Evans PH. Caution needed in introducing warfarin treatment. Br Med J 1995; 311: 560-561.
49. Gustafsson C, Asplund K, Britton M, Norrving B, Olsson B, Marke LA. Cost-effectiveness of primary stroke prevention in atrial fibrillation: Swedish national perspective. Br Med J 1992; 305: 1457-1460.
50. Caro JJ, Groome PA, Flegel KM. Atrial fibrillation and anticoagulation: from randomised trials to practice. Lancet 1993; 341: 1381-1384.
51. Singer DE, Hughes RA, Gress DR, et al. for the BAATAF Investigators. The effect of aspirin on the risk of stroke in patients with nonrheumatic atrial fibrillation: the BAATAF study. Am Heart J 1992; 124: 1567-1573.
52. Lip GYH, Lowe GDO. ABC of Atrial Fibrillation: Antithrombotic treatment for atrial fibrillation. Br Med J 1996; 312: 45-49.
53. Levine HJ, Pauker SG, Salzman EW, Eckman MH. Antithrombotic therapy in valvular heart disease. Chest 1992; 102 (4 Suppl) 434S-444S.
54. Stein PD, Alpert JS, Copeland J, Dalen JE, Goldman S, Turpie AG. Antithrombotic therapy in patients with mechanical and biological prostehtic heart valves. Chest 1992; 102 (4 Suppl): 445S-455S.
55. Gohlke-Barwolf C, Acar J, Burckhardt D, et al. Guidelines for prevention of thromboembolic events in valvular heart disease. Ad Hoc Committee of the Working Group on Valvular Heart Disease, European Society of Cardiology. J Heart Valve Dis 1993; 3: 398-410.
56. Lip GYH, Tean KN, Dunn FG. Treatment of atrial fibrillation in a district general hospital. Br Heart J 1994; 71: 92-95.
57. Laupacis A, Albers G, Dalen J, Dunn M, Feinberg W, Jacobson A. Antithrombotic therapy in atrial fibrillation. Chest 1995; 108 (Suppl): 352S-59S.
58. Levy S. Direct current cardioversion of established atrial fibrillation. Clin Cardiol 1992; 15: 445-449.
59. Lip GYH. Cardioversion of atrial fibrillation. Postgrad Med J 1995; 71: 457-465.
60. Bjerkelund CJ, Orning OM. The efficacy of anticoagulant therapy in preventing embolism related to D.C. electrical cardioversion of atrial fibrillation. Am J Cardiol 1969; 23: 208-216.
61. Mancini GBJ, Goldberger AL. Cardioversion of atrial fibrillation: consideration of embolization, anticoagulation, prophylactic pacemaker and long term success. Am Heart J 1982; 104: 617-621.
62. Sherman DG, Dyken ML, Gent M, Harrison MJG, Hart RG, Mohr JP. Antithrombotic therapy for cerebrovascular disorders. Chest 1995; 108 (suppl): 444-456S.
63. Lancaster TR, Singer DE, Sheehan MA, et al. The impact of long-term warfarin therapy on quality of life. Evidence from a randomized trial. Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. Arch Intern Med 1991; 151: 1944-1949.
64. Bern MM, Lokich JJ, Wallach SR, et al. Very low doses of warfarin can prevent thrombosis in central venous catheters. Ann Intern Med 1990; 112: 423-428.
65. Levine M, Hirsh J, Gent M, et al. Double-blind randomised trial of very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet 1994; 343: 886-889.
66. Taylor F, Ramsay M, Voke J, Cohen H. Anticoagulation in patients with atrial fibrillation: GPs not prepared for monitoring anticoagulation. Br Med J 1993; 307: 1493.
67. Bath PMW, Prasad A, Brown MM, MacGregor GA. Survey of use of anticoagulation in atrial fibrillation. Br Med J 1993; 307: 1045.
68. Lip GYH. Does atrial fibrillation confer a hypercoagulable state? Lancet 1995; 346: 1313-1314.
69. Kumagai K, Fukunami M, Ohmori M, Kitabatake A, Kamada T, Hoki N. Increased intracardiovascular clotting in patients with chronic atrial fibrillation. J Am Coll Cardiol 1990; 16: 377-380.
70. Gustafsson C, Blomback M, Britton M, Hamsten A, Svensson J. Coagulation factors and the increased risk of stroke in nonvalvular atrial fibrillation. Stroke 1990; 21: 47-51.
71. Lip GYH, Lowe GDO, Rumley A, Dunn FG. Increased markers of thrombogenesis in chronic atrial fibrillation: Effects of warfarin therapy. Br Heart J 1995; 73: 527-533.
72. Fowkes FGR, Lowe GDO, Housley E, et al. Cross-linked fibrin degradation products, progression of peripheral arterial disease, and risk of coronary heart disease. Lancet 1993; 342: 84-86.
73. Lowe GDO, Rumley A, Yarnell JWG, Sweetnam PM, Thomas HF. Fibrin D-dimer, von Willebrand factor and tissue plasminogen activator antigens are predictors of major ischaemic heart disease: the Caerphilly study. Blood Coag Fibrinolys 1995; 6: 156-157.
74. Ridker PM, Hennekens CH, Cerskus A, Stampfer MJ. Plasma concentrations of cross-linked fibrin degradation product (D-dimer) and the risk of future myocardial infarction among apparently healthy men. Circulation 1994; 90: 2236-2240.
75. Lip GYH, Rumley A, Dunn FG, Lowe GDO. Plasma fibrinogen and fibrin D-dimer levels in atrial fibrillation: Effect of cardioversion to sinus rhythm. Int J Cardiol 1995; 51: 245-253.
76. Shaper AG, Pocock SJ, Walker M, Cohen NM, Wale CJ, Thomson AG. British Regional Heart Study: cardiovascular risk factors in middle-aged men in 24 towns. Br Med J 1981; 283: 179-186.
77. Kitchin AH, Milne JS. Longitudinal study of ischaemic heart disease in a randomly selected sample of older population. Br Heart J 1977; 39: 889-893.
78. Wolf PA, Dawber TR, Thomas E, Kannel WB. Epidemiologie assessment of chronic atrial fibrillation and the risk of stroke: The Framingham Study. Neurology 1978; 28: 973-977.
79. Benjamin EJ, Levy D, Varizi SM, D'Agostino RB, Belanger AJ, Wolf PA. Independent risk factors for atrial fibrillation in a population-based cohort. JAMA 1994; 271: 840-844.
80. Krahn AD, Manfreda J, Tate RB, Mathewson FAL, Cuddy TE. The natural history of atrial fibrillation: Incidence, Risk Factors and Prognosis in the Manitoba Follow-Up Study. Am J Med 1995; 98: 476-484.
81. Onundarson PT, Thorgeirsson G, Jonmundsson E, Sigfusson N, Hardson TH. Chronic atrial fibrillation - Epidemiologic features and 14 year followup: A case control study. Eur Heart J 1987; 3: 521-527.
82. Tanaka H, Hayashi M, Date C, et al. Epidemiologic studies of stroke in Shibata, a Japanese provisional city: Preliminary report on risk factors for cerebral infarction. Stroke 1985; 16: 773-780.
83. Flegel KM, Shipley MJ, Rose G. Risk of stroke in non-rheumatic atrial fibrillation. Lancet 1987; i: 526-529.